Eli Lilly's Wegovy rival Zepbound will help make weight-loss drug market worth $130 billion by 2030, Goldman Sachs says

• The anti-obesity drug market will be worth $130 billion by 2030, Goldman Sachs said.
• New products such as Eli Lilly's Zepbound prompted the bank to raise its forecast.
• The FDA approved the pharma giant's new weight-loss drug in November.

The market for weight-loss drugs such as Ozempic and Wegovy will keep surging due to new products including Eli Lilly's Zepbound, according to Goldman Sachs.

In a research note the bank forecast that the sector will be worth $130 billion by 2030 — $30 billion higher than its previous projection.